Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences, Inc.

We develop immunologic therapeutics and diagnostics designed to make the world a healthier place 


	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue			69.17K -	40.01K 42.16%	25.05K 37.39%
gross profit			-69.17K -	-40.01K 42.16%	-25.05K 37.39%
selling and marketing expenses		144.26K -			-25.05K -
general and administrative expenses		1.23K -	5.04M 407,727.62%	5.49M 8.96%	4.51M 17.79%
selling general and administrative expenses	3.64K -	145.49K 3,899.23%	5.04M 3,361.17%	5.49M 8.96%	4.49M 18.25%
research and development expenses		2.56K -	6.91M 269,896.81%	5.38M 22.23%	4.15M 22.90%
other expenses			-36.35K -	34.96K 196.18%
cost and expenses	3.64K -	145.49K 3,899.23%	11.95M 8,113.84%	10.86M 9.09%	8.66M 20.32%
operating expenses	3.64K -	145.49K 3,899.23%	11.95M 8,113.84%	10.86M 9.09%	8.63M 20.55%
interest expense			-41.76K -	-34.96K 16.28%
ebitda	-3.64K -	-145.49K 3,896.98%	-11.93M 8,102.42%	-10.84M 9.17%	-8.63M 20.37%
operating income	-3.64K -	-145.49K 3,896.98%	-11.95M 8,113.96%	-10.86M 9.09%	-8.66M 20.32%
depreciation and amortization		3.80K -	16.78K 342.12%	25.05K 49.26%	25.05K 0.00%
total other income expenses net	2 -	-1.49M 74,250,600%	-36.35K 97.55%	34.96K 196.18%	8.54M 24,316.24%
income before tax	-3.64K -	-1.63M 44,718.58%	-11.99M 635.16%	-10.83M 9.65%	-120.25K 98.89%
income tax expense		-3.80K -		-34.96K -	1 100.00%
net income	-3.64K -	-1.63M 44,718.58%	-11.99M 635.16%	-10.79M 9.95%	-120.25K 98.89%
weighted average shs out	8.66K -	8.66K 0%	9.40K 8.50%	17.97K 91.12%	228.64K 1,172.50%
weighted average shs out dil	8.66K -	8.66K 0%	9.40K 8.50%	17.97K 91.12%	228.64K 1,172.50%
eps	-0.42 -	-188.18 44,704.76%	-1.28K 577.55%	-600.77 52.88%	-0.53 99.91%
epsdiluted	-0.42 -	-188.18 44,704.76%	-1.28K 577.55%	-600.77 52.88%	-0.53 99.91%

COM:REVBIOSCIENCES

Revelation Biosciences, Inc.

Last Close

0.85

08/11 21:00

Market Cap

2.91M

Beta: -

Volume Today

54.90K

Avg: -

Preview